Using molecular typing to treat advanced thyroid cancer

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

This study is testing if using molecular typing can improve treatment for people with advanced thyroid cancer by looking at past patient data and enrolling new patients for real-time results.

Quick facts

• Phase: PHASE4
• Study type: Interventional
• Enrollment: 800 (estimated)
• Sex: All
• Sponsor: Fudan University (other)
• Locations: 8 sites (Fuzhou, Fujian and 7 other locations)
• Trial ID: NCT06195228 on ClinicalTrials.gov

What this trial studies

This clinical study investigates the effectiveness of molecular typing in treating advanced thyroid cancer through both retrospective and prospective approaches. The retrospective component involves analyzing data from patients treated at the hospital between January 2020 and December 2023, focusing on their treatment history, molecular test results, and survival outcomes. The prospective part will enroll patients receiving targeted therapies from January 2024 to April 2027, allowing for real-time data collection and analysis of treatment responses.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with advanced thyroid cancer that is not amenable to radical surgery and has specific genetic markers.

Not a fit: Patients currently participating in other clinical trials or those who are pregnant or lactating may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with advanced thyroid cancer.

How similar studies have performed: Other studies have shown promise in using molecular typing for targeted therapies in various cancers, suggesting potential success for this approach in thyroid cancer as well.

Eligibility criteria

Inclusion Criteria:

1. Patients volunteered to participate in this study and signed informed consent;
2. Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
3. Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements:

   1. Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC);
   2. Differentiated thyroid carcinoma not suitable for iodine therapy;
   3. Medullary thyroid carcinoma (MTC);
   4. poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC);
4. Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment.

Exclusion Criteria:

1. Patients who are participating in clinical trials of other drugs;
2. There is evidence that the patients are pregnant or lactating;
3. Other situations that are not suitable for inclusion in this study.

Where this trial is running

Fuzhou, Fujian and 7 other locations

• Fujian Cancer Hospital — Fuzhou, Fujian, China (RECRUITING)
• Henan Cancer Hospital — Zhengzhou, Henan, China (RECRUITING)
• Union Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei, China (RECRUITING)
• Caixia Liu — Hohhot, Inner Mongolia, China (RECRUITING)
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (RECRUITING)
• Shanxi Cancer Hospital — Shanxi, Taiyuan, China (RECRUITING)
• Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (RECRUITING)
• Peking union medical college hospital — Beijing, China (RECRUITING)

Study contacts

• Principal investigator: Dongmei Ji, M.D — Fudan University
• Study coordinator: Dongmei Ji, M.D

Conditions: Advanced Thyroid Cancer Patients Who Received Target Therapy